AAV Platforms for Gene Therapy Delivery

[Available On-Demand]
Search General Info
The success of gene therapies has resulted in a surge in the number of companies that are entering this arena. Many of these companies seek advice from a CDMO on the system they should use to produce their product candidate. Fujifilm Diosynth Biotechnologies is developing a platform for AAV production to be offered to companies seeking help. Our platform will consist of 1) a suspension HEk293 cell line 2) GMP grade Adenovirus helper 3) GMP rep/cap plasmid representing several AAV serotypes 4) a GOI plasmid that a candidate can be inserted in and 5) a selection of tools for in-process and release testing.

Speaker - Steve Pincus, PhD, Head of Science and Innovation, FUJIFILM Diosyth Biotechnologies